DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|BC | LOCK|TSy | LOCK|j&Mt&F |
DSM-Firmenich Earnings: Sales Guidance Raised and Margin Path Intact; Shares Fairly Valued
DSM-Firmenich reported 5% third-quarter organic sales growth and raised its 2026 growth outlook to about 5% from 2%-4%. Adjusted EBITDA rose 8% on a like-for-like basis, with a 20.4% margin. Shares were flat intraday after opening about 7% lower on Nov. 4.
